Cequent

Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research

...racts CAMBRIDGE, Mass., April 15 /PRNewswire/ -- cequent Pharmaceuticals, a pioneer in the development of n...cinoma, ovarian cancer, and others. About cequent Pharmaceuticals, Inc. ( www.cequentpharma.com ) An early-stage biopharmaceutical company, cequent is pioneering the development of novel therapeutic...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

... CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- cequent Pharmaceuticals, a pioneer in the development of n...ncer, and there is no medical treatment available. cequent will present its findings, the first-ever proof of... implicated in the progression of a disease," said cequent President and CEO, Peter Parker. "We have shown pr...

Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008

... CAMBRIDGE, Mass., April 30 /PRNewswire/ -- cequent Pharmaceuticals, a pioneer in the development of n...a non-human primate model -- an important step for cequent in the development of tkRNAi-based drugs for human...eline are based on this tkRNAi technology. About cequent Pharmaceuticals, Inc. An early-stage biopharmace...

Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles

...s pipeline of clinical drug candidates. About cequent Pharmaceuticals, Inc. An early-stage biopharmaceutical company, cequent is pioneering the development of novel therapeutic...ly held company based in Cambridge, Massachusetts, cequent was established in 2006 with seed funding from Amp...

Cequent in Biological Technology

Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.

Dr. Lieberman, of Harvard Medical School, is a prominent expert on RNAi delivery for therapeutic uses; Dr. Courvalin, of the Institut Pasteur, Paris, France, is foremost authority on bacterial genetic transfer CAMBRIDGE, Mass., Oct. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in ...

Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors

CAMBRIDGE, Mass., May 5 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Michael D. Taylor, Ph.D., has joined the company's board of directors. Dr. Taylor is president and...

TriMas Corporation's Cequent Group Acquires Chem-Chrome, Inc.

TriMas Corporation, a growth company of diversified businesses, announced today that its Cequent Transportation Accessories Group has acquired Chem-Chrome, Inc., a provider of zinc plating services. Chem-Chrome is headquartered in Schofield, Wis. and has been a longtime processor for Cequent's Trai...

Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases

... CAMBRIDGE, Mass., June 2 /PRNewswire/ -- cequent Pharmaceuticals, a pioneer in the development of n...s a scientist in 2007. Today, he leads the team of cequent researchers developing drug candidates using Ceque... our rapid progress over the past 18 months," said cequent President and CEO, Peter Parker. "We started with ...

Cequent Names Ted Hibben Chief Business Officer

... CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- cequent Pharmaceuticals, a pioneer in the development of n...any as chief business officer. Mr. Hibben comes to cequent from Coley Pharmaceutical Group, where he was most...velopment against multiple diseases. Ted brings to cequent a wealth of experience orchestrating a full range ...

Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo

... CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- cequent Pharmaceuticals, a pioneer in the development of n... target the individual forms of the disease," said cequent President and CEO, Peter Parker. "When we started ...l further validate in in vivo animal trials before cequent selects the single target to be the subject of the...